NeoGenomics And German Breast Group Highlight Jun. 2 Presentation New Data Demonstrating Clinical Potential Of RaDaR MRD Assay In HR+/HER2- Breast Cancer
Benzinga · 1d ago
Neogenomics Inc: Statement of changes in beneficial ownership of securities
Press release · 4d ago
Neogenomics Inc: Securities to be offered to employees in employee benefit plans
Press release · 5d ago
Neogenomics Inc: Current report
Press release · 05/30 21:33
Neogenomics Inc: Initial statement of beneficial ownership of securities
Press release · 05/24 22:11
NeoGenomics: What Lies Ahead
Seeking Alpha · 05/18 18:00 featured highlights include First Watch Restaurant, NeoGenomics and Universal Stainless & Alloy Products
NASDAQ · 05/17 12:16
NeoGenomics cut to market perform at Raymond James on valuation run-up
Seeking Alpha · 05/16 19:14
Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2023
Benzinga · 05/16 15:00
Raymond James Downgrades NeoGenomics to Market Perform
Benzinga · 05/16 11:10
3 Best Breakout Stocks to Invest in for Superlative Returns
NASDAQ · 05/16 10:59
Power Shift: China's EV Market, Impact On Western Brands, And Some Trading Ideas
Seeking Alpha · 05/15 12:00
Webull provides a variety of real-time NEO stock news. You can receive the latest news about Neogenomics Inc through multiple platforms. This information may help you make smarter investment decisions.
About NEO
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories. The Company operates through two segments: the Clinical Services Segment and the Pharma Services Segment. The Clinical Services segment provides various clinical testing services to community-based pathology practices, oncology practices, hospital pathology labs, reference labs, and academic centers with reimbursement from various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment supports pharmaceutical firms in their drug development programs by providing testing services and data analytics for clinical trials and research. The Company offers testing services, which include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry (IHC) and digital imaging, molecular testing and morphologic analysis. It operates testing laboratories in United States, Europe and Asia.